Compare DexCom, Inc. (DXCM) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Solaredge Technologies Inc — how do they compare? DexCom, Inc. trades at $77.86 (market cap $28.06B), while Solaredge Technologies Inc trades at $53.74 (market cap $3.32B). The key difference: DexCom, Inc. is far larger — about 8.5× Solaredge Technologies Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | SEDG | |
|---|---|---|
Market Cap | $28.06B | $3.32B |
Sector | Health | Technology |
52-Week High | $89.53 | $78.51 |
52-Week Low | $54.84 | $24.42 |
Enterprise Value | $27.03B | $3.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
SolarEdge Technologies (SEDG) trades at $55.52, up 6.5% on the day, reflecting volatile solar sector momentum. The stock shows a bullish technical signal with moving averages supporting an uptrend, while fundamentals reveal significant challenges including a net income margin of -28.56% and negative ROE of -72.5% for 2025. Recent earnings have been mixed, with a Q1 2026 miss but prior beats, as the company navigates a difficult residential solar market. Cash flow improved to positive $138.6M in 2025 after negative periods, though revenue declined sharply from 2022-2023 peaks.
The outlook remains cautious with analyst consensus at 'Hold' (58.34%) and a price target of $35.65 below current trading. Opportunities exist in AI data center power demand and European market strength, but risks include persistent profitability challenges, high debt-to-asset ratio of 25.71%, and policy uncertainty affecting solar adoption. The stock trades near resistance at $56, with support at $55.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
